{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:18:22Z","timestamp":1783477102735,"version":"3.55.0"},"reference-count":40,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The UGT1A1 enzyme is involved in the metabolism of bilirubin and numerous medications. Unconjugated hyperbilirubinemia, commonly presented as Gilbert syndrome (GS), is a result of decreased activity of the UGT1A1 enzyme, variable number of TA repeats in the promoter of the\n                    <jats:italic>UGT1A1<\/jats:italic>\n                    gene affects enzyme activity. Seven and eight TA repeats cause a decrease of UGT1A1 activity and risk GS alleles, while six TA repeats contribute to normal UGT1A1 activity and non-risk GS allele. Also, the\n                    <jats:italic>UGT1A1<\/jats:italic>\n                    (TA)\n                    <jats:sub>n<\/jats:sub>\n                    promoter genotype is recognized as a clinically relevant pharmacogenetic marker. The aim of this study was to assess diagnostic value of\n                    <jats:italic>UGT1A1<\/jats:italic>\n                    (TA)\n                    <jats:sub>n<\/jats:sub>\n                    promoter genotyping in pediatric GS patients. Correlation of the\n                    <jats:italic>UGT1A1<\/jats:italic>\n                    (TA)\n                    <jats:sub>n<\/jats:sub>\n                    genotypes and level of unconjugated bilirubin at diagnosis and after hypocaloric and phenobarbitone tests in these patients was analyzed. Another aim of the study was to assess pharmacogenetic potential of\n                    <jats:italic>UGT1A1<\/jats:italic>\n                    (TA)\n                    <jats:sub>n<\/jats:sub>\n                    variants in Serbia. Fifty-one pediatric GS patients and 100 healthy individuals were genotyped using different methodologies, polymerase chain reaction (PCR) followed by acrylamide electrophoresis, fragment length analysis and\/or DNA sequencing. Concordance of the\n                    <jats:italic>UGT1A1<\/jats:italic>\n                    (TA)\n                    <jats:sub>n<\/jats:sub>\n                    promoter risk GS genotypes with GS was found in 80.0% of patients. Therefore,\n                    <jats:italic>UGT1A1<\/jats:italic>\n                    (TA)\n                    <jats:sub>n<\/jats:sub>\n                    promoter genotyping is not a reliable genetic test for GS, but it is useful for differential diagnosis of diseases associated with hyperbilirubinemia. Level of bilirubin in pediatric GS patients at diagnosis was\n                    <jats:italic>UGT1A1<\/jats:italic>\n                    (TA)\n                    <jats:sub>n<\/jats:sub>\n                    promoter genotype-dependent. We found that the frequency of pharmacogenetic relevant\n                    <jats:italic>UGT1A1<\/jats:italic>\n                    (TA)\n                    <jats:sub>n<\/jats:sub>\n                    promoter genotypes was 63.0%, pointing out that\n                    <jats:italic>UGT1A1<\/jats:italic>\n                    (TA)\n                    <jats:sub>n<\/jats:sub>\n                    promoter genotyping could be recommended for preemptive pharmacogenetic testing in Serbia.\n                  <\/jats:p>","DOI":"10.2478\/bjmg-2018-0012","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T05:31:23Z","timestamp":1540963883000},"page":"59-68","source":"Crossref","is-referenced-by-count":11,"title":["<i>UGT1A1<\/i>\n                    (TA)\n                    <sub>n<\/sub>\n                    promoter genotype: Diagnostic and population pharmacogenetic marker in Serbia"],"prefix":"10.2478","volume":"21","author":[{"given":"M","family":"Vukovic","sequence":"first","affiliation":[{"name":"Department for Medical Genetics, University Clinical Centre of the Republic of Srpska , Banja Luka , Bosnia and Hercegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Radlovic","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nutrition, University Children\u2019s Hospital, School of Medicine, University of Belgrade , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Lekovic","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Nutrition, University Children\u2019s Hospital, School of Medicine, University of Belgrade , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Vucicevic","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Medical Sciences, University of Kragujevac , Kragujevac , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Maric","sequence":"additional","affiliation":[{"name":"Clinic for Children Diseases, University Clinical Centre of the Republic of Srpska , Banja Luka , Bosnia and Hercegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Kotur","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Gasic","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ugrin","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Stojiljkovic","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Dokmanovic","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Children\u2019s Hospital, School of Medicine, University of Belgrade , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Zukic","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Pavlovic","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"key":"2026070802021074247_j_bjmg-2018-0012_ref_001_w2aab2b8c35b1b7b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Nagar S, Blanchard RL. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT)1A family members and its role in patient response to irinotecan. Drug Metab Rev. 2006; 38(3): 393-409.","DOI":"10.1080\/03602530600739835"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_002_w2aab2b8c35b1b7b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Barbarino JM, Haidar CE, Klein TE, Altman RB. PharmGKB summary: Very important information for UGT1A1. Pharmacogenet Genomics. 2014; 24(3): 177-183.","DOI":"10.1097\/FPC.0000000000000024"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_003_w2aab2b8c35b1b7b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK, et al. Thirteen UDP-glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics. 2001; 11(4): 357-368.","DOI":"10.1097\/00008571-200106000-00011"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_004_w2aab2b8c35b1b7b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, et al. Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem. 2000; 275(46): 36164-36171.","DOI":"10.1074\/jbc.M002180200"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_005_w2aab2b8c35b1b7b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Strassburg CP, Nguyen N, Manns MP, Tukey RH. Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Mol Pharmacol. 1998; 54(4): 647-654.","DOI":"10.1016\/S0026-895X(24)13065-9"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_006_w2aab2b8c35b1b7b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Wisnumurti D, Sribudiani Y, Porsch RM, Maskoen AM, Abdulhamied LI, Rahayuningsih SE, et al. UGT1A1 genetic variations and haplotype associated with neonatal hyperbilirubinemia in Indonesian population. Biomed Res Int. 2018; 2018: 9425843. doi: 10.1155\/2018\/9425843.","DOI":"10.1155\/2018\/9425843"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_007_w2aab2b8c35b1b7b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Marques SC, Ikediobi ON. The clinical application of UGT1A1 pharmacogenetic testing: Gene-environment interactions. Hum Genomics. 2010; 4(4): 238-249.","DOI":"10.1186\/1479-7364-4-4-238"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_008_w2aab2b8c35b1b7b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert\u2019s syndrome. N Engl J Med. 1995; 333(18): 1171-1175.","DOI":"10.1056\/NEJM199511023331802"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_009_w2aab2b8c35b1b7b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Aono S, Adachi Y, Uyama E, Yamada Y, Keino H, Nanno T, et al. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert\u2019s syndrome. Lancet. 1995; 345(8955): 958-959.","DOI":"10.1016\/S0140-6736(95)90702-5"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_010_w2aab2b8c35b1b7b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Bosma P, Chowdhury JR, Jansen PH. Genetic inheritance of Gilbert\u2019s syndrome. Lancet. 1995; 346(8970): 314-315.","DOI":"10.1016\/S0140-6736(95)92203-2"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_011_w2aab2b8c35b1b7b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Radlovi\u0107 N. Hereditary hyperbilirubinemias. Srp Arh Celok Lek. 2014; 142(3-4): 257-260.","DOI":"10.2298\/SARH1404257R"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_012_w2aab2b8c35b1b7b1ab2b1c12Aa","unstructured":"Radu P, Atsom J. Gilbert\u2019s syndrome-clinical and pharmacological implications. Isr Med Assoc J. 2001; 3(8): 593-598."},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_013_w2aab2b8c35b1b7b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Radlovi\u0107 N, Lekovi\u0107 Z, Mladenovi\u0107 M, Risti\u0107 D, Radlovi\u0107 V, Leki\u0107 V, et al. Gilbert\u2019s syndrome in children \u2013 Our experience. Srp Arh Celok Lek. 2007; 135(5-6): 317-320.","DOI":"10.2298\/SARH0706317R"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_014_w2aab2b8c35b1b7b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Radlovi\u0107 N, Risti\u0107 D, Brdar R, Jani\u0107 N, Lekovi\u0107 Z, Jani\u0107 D, et al. Association of hereditary elliptocytosis and Gilbert\u2019s syndrome as the cause of biliary calculosis: Case report. Srp Arh Celok Lek. 2011; 139(5-6): 386-389.","DOI":"10.2298\/SARH1106386R"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_015_w2aab2b8c35b1b7b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Memon N, Weinberger BI, Hegyi T, Aleksunes LM. Inherited disorders of bilirubin clearance. Pediatr Res. 2016; 79(3): 378-386.","DOI":"10.1038\/pr.2015.247"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_016_w2aab2b8c35b1b7b1ab2b1c16Aa","unstructured":"Pharmacogenomics Knowledge Base (https:\/\/www.pharmgkb.org) [accessed: April 10 2018]"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_017_w2aab2b8c35b1b7b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Ha VH, Jupp J, Tsang RY. Oncology drug dosing in Gilbert Syndrome associated with UGT1A1: A summary of the literature. Pharmacotherapy. 2017; 37(8): 956-972.","DOI":"10.1002\/phar.1946"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_018_w2aab2b8c35b1b7b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"de Morais SM, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert\u2019s syndrome. Gastroenterology. 1992; 102(2): 577-586.","DOI":"10.1016\/0016-5085(92)90106-9"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_019_w2aab2b8c35b1b7b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Berg AO, Armstrong K, Botkin J, Calonge N, Haddow J, Kaye C, et al. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med. 2009; 11(1): 15-20.","DOI":"10.1097\/GIM.0b013e31818efd9d"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_020_w2aab2b8c35b1b7b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, et al. Mechanism of indinavir-induced hyper-bilirubinemia. Proc Natl Acad Sci USA. 2001; 98(22): 12671-12676.","DOI":"10.1073\/pnas.231140698"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_021_w2aab2b8c35b1b7b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Radojkovic D, Kusic J. Silver staining of denaturing gradient gel electrophoresis gels. Clin Chem. 2000; 46(6 Pt 1): 883-884.","DOI":"10.1093\/clinchem\/46.6.883"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_022_w2aab2b8c35b1b7b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F, et al. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood. 2009; 113(14): 3307-3313.","DOI":"10.1182\/blood-2008-03-148874"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_023_w2aab2b8c35b1b7b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Karan-Djurasevic T, Palibrk V, Kostic T, Spasovski V, Nikcevic G, Srzentic S, et al. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2012; 12(4): 252-260.","DOI":"10.1016\/j.clml.2012.03.005"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_024_w2aab2b8c35b1b7b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet. 2005; 76(5): 887-893.","DOI":"10.1086\/429864"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_025_w2aab2b8c35b1b7b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Radoi VE, Ursu RI, Poenaru E, Arsene C, Bohiltea CL, Bohiltea R. Frequency of the UGT1A1*28 polymorphism in a Romanian cohort of Gilbert Syndrome individuals. J Gastrointestin Liver Dis. 2017; 26(1): 25-28.","DOI":"10.15403\/jgld.2014.1121.261.ugt"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_026_w2aab2b8c35b1b7b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Torres AK, Escart\u00edn N, Monz\u00f3 C, Guzm\u00e1n C, Ferrer I, Gonz\u00e1lez-Munoz C, et al. Genetic susceptibility to Gilbert\u2019s syndrome in a Valencian population; efficacy of the fasting test. Rev Clin Esp. 2017; 217(1): 1-6.","DOI":"10.1016\/j.rceng.2016.10.004"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_027_w2aab2b8c35b1b7b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Viennas E, Komianou A, Mizzi C, Stojiljkovic M, Mitropoulou C, Muilu J, et al. Expanded national database collection and data coverage in the FINDbase worldwide database for clinically relevant genomic variation allele frequencies. Nucleic Acids Res. 2017; 45(D1): D846-D853.","DOI":"10.1093\/nar\/gkw949"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_028_w2aab2b8c35b1b7b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Beutler E, Gelbart T, Demina A. Racial variability in the UDP glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA. 1998; 95(14): 8170-8174.","DOI":"10.1073\/pnas.95.14.8170"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_029_w2aab2b8c35b1b7b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Premawardhena A, Fisher CA, Liu YT, Verma IC, de Silva S, Arambepola M, et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): Hematologic and evolutionary implications. Blood Cells Mol Dis. 2003; 31(1): 98-101.","DOI":"10.1016\/S1079-9796(03)00071-8"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_030_w2aab2b8c35b1b7b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Bajro MH, Josifovski T, Panovski M, Jankulovski N, Nestorovska AK, Matevska N, et al. Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer. Cancer Genet. 2012; 205(4): 163-167.","DOI":"10.1016\/j.cancergen.2012.01.015"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_031_w2aab2b8c35b1b7b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"Kapedanovska Nestorovska A, Jakovski K, Naumovska Z, Hiljadnikova Bajro M, Sterjev Z, Eftimov A, et al. Distribution of the most common genetic variants associated with a variable drug response in the population of the Republic of Macedonia. Balkan J Med Genet. 2015; 17(2): 5-14.","DOI":"10.2478\/bjmg-2014-0069"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_032_w2aab2b8c35b1b7b1ab2b1c32Aa","unstructured":"Marinkovi\u0107 N, Pasali\u0107 D, Grskovi\u0107 B, Ferencak G, Honovi\u0107 L, Rukavina AS. Genotype frequencies of UDP-glucuronosyltransferase 1A1 promoter gene polymorphism in the population of healthy Croatian pre-scholars. Coll Antropol. 2008; 32(3): 725-729."},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_033_w2aab2b8c35b1b7b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Mlakar SJ, Ostanek B. Development of a new DHPLC assay for genotyping UGT1A (TA)n polymorphism associated with Gilbert\u2019s syndrome. Biochem Med (Zagreb). 2011; 21(2): 167-173.","DOI":"10.11613\/BM.2011.026"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_034_w2aab2b8c35b1b7b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Ostanek B, Furlan D, Mavec T, Lukac-Bajalo J. UGT1A1(TA)n promoter polymorphism \u2014 A new case of a (TA)8 allele in Caucasians. Blood Cells Mol Dis. 2007; 38(2): 78-82.","DOI":"10.1016\/j.bcmd.2006.10.160"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_035_w2aab2b8c35b1b7b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Biondi ML, Turri O, Dilillo D, Stival G, Guagnellini E. Contribution of the TATA-box genotype (Gilbert syndrome) to serum bilirubin concentrations in the Italian population. Clin Chem. 1999; 45(6 Pt 1): 897-898.","DOI":"10.1093\/clinchem\/45.6.897"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_036_w2aab2b8c35b1b7b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, Loriot MA, et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam Clin Pharmacol. 2015; 29(3): 219-237.","DOI":"10.1111\/fcp.12117"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_037_w2aab2b8c35b1b7b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, et al.; CPIC. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir prescribing. Clin Pharmacol Ther. 2016; 99(4): 363-369.","DOI":"10.1002\/cpt.269"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_038_w2aab2b8c35b1b7b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"Culley CL, Kiang TK, Gilchrist SE, Ensom MH. Effect of the UGT1A1 28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: A systematic review. Ann Pharmacother. 2013; 47(4): 561-72.","DOI":"10.1345\/aph.1R550"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_039_w2aab2b8c35b1b7b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"Fujita K, Sugiyama M, Akiyama Y, Ando Y, Sasaki Y. The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1. Cancer Chemother Pharmacol. 2011; 67(1): 237-241.","DOI":"10.1007\/s00280-010-1445-3"},{"key":"2026070802021074247_j_bjmg-2018-0012_ref_040_w2aab2b8c35b1b7b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"de Souza MM, Vaisberg VV, Abreu RM, Ferreira AS, da Silva Ferreira C, Nasser PD, et al. UGT1A1 28 relationship with abnormal total bilirubin levels in chronic hepatitis C patients: Outcomes from a case-control study. Medicine (Baltimore). 2017; 96(11): e6306.","DOI":"10.1097\/MD.0000000000006306"}],"container-title":["Balkan Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/bjmg\/21\/1\/article-p59.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/bjmg-2018-0012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:05:59Z","timestamp":1783476359000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/bjmg-2018-0012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,10,29]]},"published-print":{"date-parts":[[2018,10,29]]}},"alternative-id":["10.2478\/bjmg-2018-0012"],"URL":"https:\/\/doi.org\/10.2478\/bjmg-2018-0012","relation":{},"ISSN":["1311-0160"],"issn-type":[{"value":"1311-0160","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}